Literature DB >> 23985256

[Expression of molecular markers detected by immunohistochemistry and risk of lymph node metastasis in stage T1 and T2 colorecrectal cancers].

Fu-long Wang1, De-sen Wan, Zhen-hai Lu, Yu-jing Fang, Li-ren Li, Gong Chen, Xiao-jun Wu, Pei-rong Ding, Ling-heng Kong, Jun-zhong Lin, Zhi-zhong Pan.   

Abstract

OBJECTIVE: To study the molecular risk factors of lymph node metastasis in stage T1 and T2 colorectal cancers by tissue microarray and immunohistochemistry techniques.
METHODS: Two hundred and three patients with stage T1 and T2 colorectal carcinoma who underwent radical surgery from 1999 to 2010 in our department were included in this study. Their clinicopathological data were retrospectively analyzed. Expression of the following 14 molecular markers were selected and assayed by tissue microarray and immunohistochemistry: VEGFR-3, HER2, CD44v6, CXCR4, TIMP-1, EGFR, IGF-1R, IGF-2, IGFBP-1, ECAD, MMP-9, RKIP, CD133, MSI. Chi-squared test and logistic regression were used to evaluate the variables as potential risk factors for lymph node metastasis.
RESULTS: The positive expression rates of biomarkers were as following: VEGFR-3 (44.3%), EGFR (30.5%), HER-2 (28.1%), IGF-1R (63.5%), IGF-2 (44.8%), IGFBP-1 (70.9%), ECAD (45.8%), CD44v6 (51.2%), MMP-9 (44.3%), TIMP-1 (41.4%), RKIP (45.3%), CXCR4 (40.9%), and CD133 (49.8%). The positive rate of MSI expression was 22.2%. Both univariate and multivariate analyses showed that VEGFR-3, HER-2, and TIMP-1 were significant predictors of lymph node metastasis. Univariate analysis showed that CD44v6 and CXCR4 were significant significant predictors of lymph node metastasis.
CONCLUSIONS: VEGFR-3, HER2 and TIMP-1 are independent factors for lymph node metastasis in stage T1 and T2 colorectal cancers.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23985256     DOI: 10.3760/cma.j.issn.0253-3766.2013.04.008

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  2 in total

1.  CD44v6 overexpression related to metastasis and poor prognosis of colorectal cancer: A meta-analysis.

Authors:  Ji-Lin Wang; Wen-Yu Su; Yan-Wei Lin; Hua Xiong; Ying-Xuan Chen; Jie Xu; Jing-Yuan Fang
Journal:  Oncotarget       Date:  2017-02-21

Review 2.  CD133 expression correlates with clinicopathologic features and poor prognosis of colorectal cancer patients: An updated meta-analysis of 37 studies.

Authors:  Rongyong Huang; Dan Mo; Junrong Wu; Huaying Ai; Yiping Lu
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.